Allergan inks $165M licensing deal for urology drug; Orexigen files third big obesity drug app

 @FierceBiotech:  Biotech inspired $295B in M&A deals over the last decade. Article | Follow @FierceBiotech

 @JohnCFierce: Cautionary tale, ARQL conference call: Analyst raises recent lung cancer failures in Ph3 for Novelos and Antisoma. Tricky field. | Follow @JohnCFierce

> Allergan is beefing up its urology pipeline, licensing in a late-stage therapy from Serenity to prevent frequent night-time urination for $43 million upfront and up to $122 million in milestones. The drug, Ser-120, is a nasally administered therapy. Allergan, which is best known for its Botox wrinkle therapy, also sells Sanctura, which is used to treat overactive bladder. Story

> Orexigen has filed for an approval of its weight-loss drug Contrave, one of three closely watched obesity therapies now in front of the FDA. Vivus and Arena Pharmaceuticals are also vying for an approval of their drugs, setting up the possibility of a single expert panel review for all three. Report

> Scotland's ProStrakan says that the FDA wants to see more data on its pain ointment, delaying any approval for the therapy. "ProStrakan intends to meet with the FDA in the near future and discuss these requirements, and the potential timetable, in more detail," the company says. Report

> Vanda Pharmaceuticals CBO Chip Clark is leaving his post with plans to either join an existing start-up or found a company of his own. Story

> AMAG Pharmaceuticals struck a marketing deal with Takeda for its anemia drug Feraheme that's worth up to $280 million. Feraheme is approved for chronic kidney disease. Story

> The FDA has approved Asclera for the treatment of small varicose veins. Story

> Ricerca Biosciences announced that it had struck a business development pact with Japan's Life Science Partner. Release

And Finally... An international team of scientists has decoded the genome of a songbird--the Australian zebra finch--to reveal intriguing clues about the genetic basis and evolution of vocal learning. Report

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.